公开(公告)号：EP4331587A1

公开(公告)日：2024-03-06

申请号：EP22796144.8

申请日：2022-04-27

申请人： Oncocross Co., Ltd. ,  Jeil Pharmaceutical Co., Ltd.

发明人： KIM, Yi Rang ,  PARK, Sang Yun ,  YANG, Ga Eul

IPC分类号： A61K31/5377 ,  A61P3/00 ,  A61P3/04 ,  A61P1/16 ,  A61P35/00

摘要： The present invention relates to a composition for preventing or treating metabolic diseases, containing 10-ethoxy-8-(morpholinomethyl)-2,3,4,6-tetrahydrobenzo[h][1,6]naphthyridin-5(1H)-one, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a salt hydrate thereof as an active ingredient. Due to an adipocyte differentiation inhibitory effect, a fat accumulation inhibitory effect, an NAFLD inhibitory effect, and an NASH-induced fibrosis inhibitory effect of the composition, it is possible to prevent or treat metabolic diseases including nonalcoholic steatohepatitis (NASH), NASH-associated liver fibrosis, nonalcoholic fatty liver (NAFL), and NAFLD-associated liver fibrosis, fatty liver, and obesity.

公开(公告)号：EP4394779A1

公开(公告)日：2024-07-03

申请号：EP22873185.7

申请日：2022-09-22

申请人： Oncocross Co., Ltd.

发明人： LEE, Young Heun ,  KIM, Yi Rang ,  KANG, Ji Hoon

IPC分类号： G16B40/20 ,  G16B25/10 ,  G16B30/10 ,  C12Q1/6886 ,  G01N33/574 ,  G16B35/00 ,  G16B50/00

CPC分类号： C12Q1/6886 ,  G01N33/574 ,  G16B25/10 ,  G16B40/20 ,  G16H50/20

摘要： A method for diagnosing cancer of unknown primary site by using artificial intelligence is disclosed. A method for diagnosing cancer of unknown primary site by using artificial intelligence, according to one embodiment of the present invention, includes the steps of: generating gene expression pattern information of a sample collected from tissue in which metastatic cancer has occurred; removing gene expression pattern information derived from pre-learned tissue from the gene expression pattern information of the sample collected from the tissue in which the metastatic cancer has occurred; comparing the gene expression pattern information from which the gene expression pattern information derived from the tissue has been removed with pre-learned gene expression pattern information for each cancer type; and specifying a primary site of the sample collected from the tissue in which the metastatic cancer has occurred.

公开(公告)号：EP4321161A1

公开(公告)日：2024-02-14

申请号：EP22784860.3

申请日：2022-03-31

申请人： Oncocross Co., Ltd.

发明人： KIM, Yi Rang

IPC分类号： A61K31/4375 ,  A61K31/352 ,  A61P13/12 ,  A23L33/10

摘要： The present disclosure relates to a use of (R)-4-{(R)-1-[7-(3,4,5-trimethoxyphenyl)-[1,6] naphthyridin-5-yloxy]-ethyl}pyrrolidin-2-one in treating kidney disease. According to the present disclosure, (R)-4-{(R)-1-[7-(3,4,5-trimethoxy-phenyl)-[1,6] naphthyridin-5-yloxy]-ethyl}pyrrolidin-2-one of the present disclosure palliates clinical symptoms and alleviates renal failure and renal injury through reduction of blood glucose levels and insulin resistance in diabetic nephrosis animal models. Thus, the compound may be advantageously applied to a use for preventing or treating kidney diseases, especially diabetic renal diseases.

公开(公告)号：EP4321160A1

公开(公告)日：2024-02-14

申请号：EP22784859.5

申请日：2022-03-31

申请人： Oncocross Co., Ltd.

发明人： KIM, Yi Rang

IPC分类号： A61K31/4375 ,  A61K31/352 ,  A61P3/10 ,  A23L33/10

摘要： The present invention relates to a use of (R)-4-{(R)-1-[7-(3,4,5-trimethoxyphenyl)-[1,6] naphthyridine-5-yloxy]-ethyl}pyrrolidine-2-one for treating diabetes. According to the present invention, (R)-4-{(R)-1-[7-(3,4,5-trimethoxy-phenyl)-[1,6] naphthyridine-5-yloxy]-ethyl}pyrrolidine-2-one of the present invention alleviates clinical symptoms of diabetes, reduces blood sugar, reduces blood glucose concentrations and insulin-resistance and reduces liver and kidney damages in an animal model of insulin-resistant diabetes, and thus can be effectively used for preventing or treating diabetes, especially insulin-resistant diabetes.